54 results about "Fluoxetine" patented technology

The invention relates to a preparation method of an effective part extract of n-butyl alcohol of Eupatorium chinense and application of the effective part extract in treatment of diabetes complicated with depression. The technical scheme of the invention is to provide an extract of the n-butyl alcohol effective part of the eupatorium chinense, which can be used for treating diabetes complicated by depression diseases. In-vitro experiments show that the eupatorium chinense extract has an inhibition effect on acetylcholin esterase (AChE). In-vivo animal experiments find that classical anti-diabetes and depression treatment drugs, namely metformin hydrochloride and fluoxetine hydrochloride, are taken as positive controls, experimental research on the treatment effect of the effective part extract of the n-butyl alcohol of the eupatorium chinense on mice suffering from diabetes complicated with depression is developed, and research results show that the extract can regulate insulin resistance and can be used for treating diabetes complicated with depression. The glycometabolism of mice with diabetes mellitus complicated with depression is improved, and the depression symptom is improved. The extract has a remarkable effect of treating diabetes mellitus complicated with depression, has a good effect of treating diabetes mellitus complicated with depression, and is expected to be developed into a new natural medicine for treating diabetes mellitus complicated with depression.

The invention provides an anti-depression composition and a preparation method thereof. The composition is prepared from the following components in parts by mass: 1 part of saikoside D, 2 to 6 parts of saikoside A, 20 to 25 parts of paeoniflorin, 6 to 9 parts of albiflorin, 12 to 15 parts of apiose liquiritin, 2 to 4 parts of apiose isoliquiritin and 4 to 6 parts of atractylenolide I. Compared with western medicine fluoxetine and classic famous formula Xiaoyao powder which are sold on the market under the clinical equivalent dosage condition in the depression cell and depression animal experiment dimension, cell experiments and animal experiments both show that the medicine effect of the anti-depression composition is far higher than the anti-depression effect of the western medicine fluoxetine, and meanwhile, the anti-depression composition has the advantages that the anti-depression effect of the anti-depression composition is greatly improved. The medicine effect is higher than the anti-depression effect of the whole prescription of the Xiaoyao powder

The invention provides lactobacillus plantarum for regulating mood health and resisting depression and application thereof, and the strain is separated from traditional pickles and is identified as lactobacillus plantarum. Experiments show that KY013 can significantly improve behavioral performance of depression model mice, and the effect of KY013 is equivalent to that of fluoxetine. The action mechanism comprises the following steps: up-regulating the levels of neurotransmitters such as 5-HT, DA, NE and GABA in hypothalamus, regulating the balance of proinflammatory factors (IL-6 and IFN-alpha) and anti-inflammatory factors (IL-10), and playing an anti-depression role through'neurotransmitter-immunity 'double ways. The KY013 disclosed by the invention can be used for developing antidepressant drugs or functional foods and the like, has the advantages of multi-target coordination, high safety and the like, and provides a new microecological preparation choice for treating depression.

The application provides an application of a motion-induced sweat extract in preparation of a medicine for treating, relieving or preventing depression and / or anxiety, and belongs to the field of biological medicine. Specifically, sweat is induced by making a healthy subject perform aerobic exercise of a specific intensity (such as 60%-80% of maximum heart rate), the sweat is collected and eluted by physiological saline, centrifuged and filtered to obtain a biologically active sweat extract. The extract is analyzed by transcriptomics and reverse transcription method to predict the anti-depression potential, and it is proved by in-vivo animal experiments that the extract can significantly improve the anhedonia, behavioral despair and anxiety-like behavior of a depression model mouse, and the effect of a high dose is equivalent to that of a first-line drug fluoxetine. The preparation raw material provided by the application is natural and safe, the preparation process is simple and the cost is low, and a new, easy-to-promote alternative strategy is provided for the prevention and treatment of depression.

The invention discloses a traditional Chinese medicine composition for treating qi deficiency and collateral arthralgia type depression. The composition is mainly prepared from the following traditional Chinese medicines in parts by weight: 25 to 400 parts of ginseng, 30 to 500 parts of cassia twig, 30 to 600 parts of radix paeoniae alba, 30 to 150 parts of radix curcumae and 30 to 150 parts of honey-fried licorice root. The composition can also comprise 20-200 parts of fresh ginger. Tests prove that the treatment effect of the composition on qi-deficiency collateral-arthralgia type depression is equivalent to or better than that of fluoxetine, the composition has remarkable treatment effects of tonifying qi and dredging collaterals while resisting depression, the symptoms of weakness, wind intolerance, gastrointestinal weakness and blood microcirculation injury of patients are effectively relieved, and the positive drug fluoxetine does not have the effects.

The invention provides a traditional Chinese medicine composition for treating qi stagnation and collateral arthralgia type depression. The composition is mainly prepared from 25 to 400 parts of radix curcumae, 30 to 500 parts of radix angelicae sinensis, 30 to 600 parts of rhizoma chuanxiong, 30 to 150 parts of radix paeoniae alba, 30 to 150 parts of cassia twig and 30 to 150 parts of poria cocos. Animal experiments show that the traditional Chinese medicine composition can effectively improve depression-like symptoms of mice with depression, the anti-depression effect of the traditional Chinese medicine composition is equivalent to that of a positive drug fluoxetine, and no obvious adverse drug reaction exists. In addition, the traditional Chinese medicine composition also has obvious curative effects of regulating qi and dredging collaterals, and the positive drug fluoxetine has no response effect. The traditional Chinese medicine composition has the advantages of simple formula, easily available raw materials, strong adaptation specificity, obvious curative effect and simple preparation process, and is suitable for industrial production.

The present disclosure relates to a pharmaceutical composition comprising a therapeutically effective amount of latrepirdine or a pharmaceutically acceptable salt thereof and an effective amount of a PK stabilizer. The PK stabilizer may be selected from the group consisting of paroxetine, fluoxetine, and quinidine or a pharmaceutically acceptable salt thereof. The PK stabilizer in the composition results in improved pharmacokinetic profile and enhanced therapeutic effect of latrepirdine. The disclosure further relates to treatment of disorders associated with noradrenergic hyperarousal using the pharmaceutical composition.

To provide anti-obesity agents to overcome defects of currently used anti-obesity agents, that is, as main types of the previously developed anti-obesity drugs, appetite suppressants acting on the central nervous system are drugs that control the action of neurotransmitters (for example, phentermine, mazindol, lorcaserin, fluoxetine and sibutramine) were mostly used, but the neurotransmitter modulators exert a wide range of effects on various physiological actions in addition to appetite suppression by numerous subtype receptors, so that the modulators are lacking in selectivity for each subtype and have a large disadvantage in that various side effects are accompanied in a case of long-term administration.SOLUTION: The present invention relates to uses of a compound of chemical formula 1 or a pharmaceutically acceptable salt thereof for the purpose of preventing or treating rare genetic obesity diseases, particularly rare genetic obesity diseases associated with a damaged melanocortin-4 receptor (MC4R) pathway.SELECTED DRAWING: None

The present invention provides a pharmaceutical composition comprising dextromethorphan, the composition comprising dextromethorphan or a pharmaceutically acceptable salt thereof, and fluoxetine or a pharmaceutically acceptable salt thereof. According to the pharmaceutical composition provided by the invention, the dextromethorphan or the pharmaceutically acceptable salt of the dextromethorphan and the fluoxetine or the pharmaceutically acceptable salt of the fluoxetine are combined according to a specific proportion, so that the pharmaceutical composition not only has an excellent synergistic effect, but also reduces the dosage of the dextromethorphan and the fluoxetine which are independently used. The invention also provides application of the pharmaceutical composition in preparation of drugs for preventing and / or treating cough and neuropsychiatric disorders, especially depression.

The application belongs to the technical field of medicines, and specifically discloses an anti-depression m-hydroxybenzoic acid compound and a preparation method and application thereof; the m-hydroxybenzoic acid compound Hyperioxides A-F provided by the application has not been reported; the six compounds have good anti-depression effects, and further research shows that the compounds Hyperioxide A, Hyperioxide D, Hyperioxide E and Hyperioxide F have significant protective effects on SH-SY5Y cells induced by corticosterone, and are superior to positive drugs fluoxetine and Luoyoutei, and can be used for developing drugs for treating depression.

The invention belongs to the technical field of biological medicines, and particularly relates to a group of synergists for anti-tuberculosis infection medicines and application of the synergists. In the invention, Vortioxetine (Vor) shows obvious activity for enhancing mycobacterium infection resistance: under the concentration of 2 mu g / mL, the MIC (minimal inhibitory concentration) of Bedaquiline to H37Rv can be reduced by about 64 times (from 0.06 mu g / mL to 0.0009375 mu g / mL), and the MIC of Bedaquiline to an Rv0678 mutant strain can be reduced by about 64 times (from 1 mu g / mL to 0.0156 mu g / mL). And the content of sertraline hydrochloride (STL) can be reduced by about 16 times and 8 times respectively. The synergistic effect of fluoxetine (FXT) is weakest and is only reduced by two times. The synergist disclosed by the invention is a drug which has been sold on the market, so that the synergist has safety and complete medication guidance. The preparation process and the production process are both perfect, the product can be quickly sold on the market, the selling price is reasonable, the market acceptability is good, and the patient compliance is high. The votioxetine or the sertraline can be used as a synergist of a medicine for resisting mycobacterium tuberculosis infection.

The application discloses a lycoctine type diterpenoid alkaloid compound and a preparation method and application thereof. 20 The diterpenoid alkaloid compound Carmaloidline E shows significant antidepressant activity in a mouse behavioral despair model experiment, is obviously superior to fluoxetine as a positive medicine, and can be used for developing antidepressant drugs.

The invention discloses application of Cacumen biotae-derived extracellular vesicles in preparation of drugs for treating anxiety, depression or insomnia. The EVs are separated and purified from cacumen biotae through a specific differential ultracentrifugation method, the EVs have a typical double-layer membrane structure, the average particle size is about 100 nm, about 1012 EVs can be extracted from each gram of cacumen biotae, and 62 volatile components are contained. Cacumen biotae EVs can be taken by PC12 cells, and corticosterone-induced neuron damage can be relieved; for chronic constraint stress model mice, anxiety behaviors and spatial learning and memory disorders can be improved, and central nervous inflammation can be inhibited; for chronic unpredictable mild stress model mice, the weight, the sucrose preference rate and the cognitive ability can be recovered, and the levels of 5-hydroxytryptamine and gamma-aminobutyric acid are increased; and for 4-chloro-DL-phenylalanine induced insomnia model mice, the sleep condition can be improved, the neurotransmitter level can be recovered, and the effect is equivalent to that of positive drugs such as citalopram, fluoxetine, diazepam and the like.

The invention provides a lipidosome preparation capable of performing brain-targeted drug delivery in a depression model, a preparation method of the lipidosome preparation and application of the lipidosome preparation in improving the anti-depression effect of fluoxetine, and belongs to the technical field of pharmaceutical preparations. The composition disclosed by the invention consists of DOPG, DSPE-PEG2000-PGP, DSPE-PEG2000, cholesterol, fluoxetine and celecoxib, and can be used for improving the anti-depression effect of fluoxetine. The double-drug-loading liposome with high entrapment efficiency and uniform particle size is prepared through a film hydration-film extrusion method, has good stability and biocompatibility, has an obvious targeting drug delivery effect in a chronic social contusion stress model, is suitable for a combined treatment strategy of depression, and has a good clinical application prospect.

The present invention belongs to the field of pharmaceutical technology, and specifically discloses a high adamantane type phloroglucinol compound, a preparation method thereof and an application thereof; the high adamantane type phloroglucinol compound Hyperichoisin C provided by the present invention has remarkable antidepressant activity, which is superior to the positive drugs fluoxetine and St. John's wort extract, and can be used for developing drugs for treating depression.

The invention belongs to the field of pharmaceutical analysis, and particularly relates to a method for detecting related substances in olanzapine or olanzapine fluoxetine hydrochloride preparations, which comprises the following steps: taking a sample to be detected, and detecting by high performance liquid chromatography under the following chromatographic conditions: a chromatographic column takes octyl silane bonded silica gel as a filler; a mobile phase A is prepared from a solution A and acetonitrile in a volume ratio of (52-54): (46-48), and a mobile phase B is prepared from a solution A and acetonitrile in a volume ratio of 30: 70. The detection method is good in system applicability, high in specificity and high in accuracy, the detection limit and the quantification limit meet the requirements of Chinese pharmacopoeia, the quality of the olanzapine or olanzapine fluoxetine hydrochloride preparation can be effectively monitored, then the quality safety of the olanzapine or olanzapine fluoxetine hydrochloride preparation is guaranteed, and the application prospect is wide.

The invention discloses a novel active peptide composition for regulating emotion and application thereof. Belongs to the technical field of active peptides. In the process of extracting new active peptides from brain peptide by taking brain peptide as a raw material, various new active peptides, including VVAVP and VVAVPGN, are found, the efficacy of the new active peptides is further studied, and experimental results show that VVAVP and VVAVPGN have a certain anti-depression effect, but when VVAVP and VVAVPGN synergistically act on mice at the same time according to a ratio of 1: 1-1: 3, the anti-depression effect of VVAVP and VVAVPGN is remarkably improved, and the anti-depression effect of VVAVP and VVAVPGN is remarkably improved. It is accidentally found that the anti-depression effect is multiplied, it is indicated that when fluoxetine and fluoxetine are mixed in a specific proportion, the synergistic effect is achieved in the anti-depression aspect, the anti-depression effect can be remarkably improved, the effect is equivalent to that of fluoxetine in a positive control group, and a new research direction is provided for research and development of anti-depression drugs.

The invention provides a traditional Chinese medicine composition for treating yin and blood deficiency type depression. The composition is mainly prepared from the following traditional Chinese medicines in parts by weight: 25 to 400 parts of colla corii asini, 25 to 400 parts of semen ziziphi spinosae, 30 to 500 parts of fructus mori, 30 to 500 parts of fructus citri sarcodactylis, 30 to 600 parts of semen persicae and 30 to 600 parts of poria cocos. The composition has the advantages of nourishing yin and blood, soothing liver-qi stagnation, promoting blood circulation to restore menstrual flow, and clearing away heart fire and soothing nerves. Animal experiments show that the traditional Chinese medicine composition can effectively improve depression-like symptoms of mice with depression, the anti-depression effect of the traditional Chinese medicine composition is equivalent to that of a positive drug fluoxetine, and no obvious adverse drug reaction exists. In addition, the composition also has a remarkable curative effect of nourishing yin and enriching blood, and a positive drug fluoxetine does not have a response effect. The composition is simple, raw materials are easy to obtain, the adaptation specificity is high, the preparation process is simple, and the composition is suitable for industrial production.

The present invention relates to use of a PGK1 inhibitor in depression or anxiety disorders. Specifically disclosed is a prophylactic and / or therapeutic effect of a PGK1 inhibitor represented by formula (I) on depression or anxiety disorders. The PGK1 inhibitor has excellent safety and efficacy, and the efficacy is superior to that of the clinical first-line drug fluoxetine.

The invention discloses application of fluoxetine in preparation of a medicine for treating epileptic seizure or brain injury. In-vivo and in-vitro experiments find that fluoxetine can inhibit epilepsy-induced ferroptosis by inhibiting ubiquitination of GPX4 protein so as to play a role in treating epileptic seizure or brain injury for the first time, and a new technical means is provided for treatment of epilepsy or brain injury.

The invention discloses application of enterobacter murine in preparation of a medicine for preventing or treating depression, and belongs to the field of medicine. The invention relates to an application of enterobacter murine in preparation of a medicine for preventing or treating depression. According to the present invention, the enterobacter muricatum is Muriaculum gardrongarter, and is preserved in the German Microbiological Culture Collection Center, and the preservation number is DSM 108194. The enterobacter muricatum can be used for preparing the enterobacter muricatum, the invention discloses application of active enterobacter murine, namely application of the active enterobacter murine in preparation of drugs for preventing or treating depression. The sucrose preference of the mouse is improved to a certain extent, the mood disorder is obviously reduced after the enterobacter murine is administered, and compared with fluoxetine, depression caused by chronic social contusion stress can be more quickly improved. The medicine is suitable for clinical popularization and use.

The application provides a tetrahedral DNA / fluoxetine hydrochloride complex, a preparation method thereof and a use thereof in treating depression, and relates to the technical field of medicines.The tetrahedral DNA / fluoxetine complex of the application is a complex formed by embedding fluoxetine or a salt thereof into base pairs between a double helix structure of a tetrahedral DNA molecule in a non-covalent combination mode.The complex of the application has a fast onset time when treating depression, can exert an antidepressant effect of fluoxetine hydrochloride at a low dose, significantly reduces related side effects generated in the process of taking medicine, and can enhance the medicine-taking compliance of patients with depression.The complex of the application has good safety and effectiveness in treating depression, and has a good application prospect in the clinical treatment of depression.

The application discloses a kind of for preventing or treating post myocardial infarction ventricular arrhythmia pharmaceutical composition, the pharmaceutical composition is by everolimus, ethmolam and fluoxetine, belongs to the field of medicine technology.Immunoblotting proves that everolimus, ethmolam and fluoxetine can inhibit fatty acid oxidation protein.In vitro and in vitro cardiac electrophysiology experiment proves that the pharmaceutical composition can effectively reduce post myocardial infarction ventricular arrhythmia susceptibility.TTC staining proves that the pharmaceutical composition can effectively reduce post myocardial infarction myocardial damage area.Based on the above composition in the regulation of post myocardial infarction ventricular arrhythmia susceptibility, it can be further developed in the clinical application of the disease.

The present invention belongs to the field of natural medicines and chemical medicines for treating and preventing depression, and specifically discloses an iridoid glycoside compound, a preparation method thereof, and use of the iridoid glycoside compound in preparing antidepressant drugs. The iridoid glycoside compound extracted from the soft-branched yellow cicada has a structure selected from allamanoid C, allamanoid E, and allamanoid H, has a novel chemical structure, and has low toxicity to normal cells. Allamanoid C, allamanoid E, and allamanoid H exhibit significant neuroprotective effects on HT22 cell damage induced by corticosterone at low concentrations, and their activity is stronger than that of the positive control drug fluoxetine hydrochloride. Allamanoid C, allamanoid E, and allamanoid H have significant antidepressant effects on mouse despair depression models (tail suspension model and forced swim model), and therefore allamanoid C, allamanoid E, and allamanoid H can be used to prepare antidepressant drugs.

The present invention relates to the field of pharmaceutical technologies, and discloses lappaconitine, a preparation method thereof, a pharmaceutical composition, and an application in antidepressant drugs; among them, the lappaconitine, a type C 18 diterpenoid alkaloid provided by the present invention shows significant antidepressant activity in the mouse behavioral despair model experiment, is significantly superior to the positive drug fluoxetine, and can be used for developing antidepressant drugs.

The application discloses a kind of inhibitors of targeting 5-HTT / HDAC double target and preparation method and application thereof.The application is based on the principle of rational drug design, and synthesizes novel small-molecule compounds with 5-HTT and HDAC inhibitory activity, multi-targets with potential antidepressant activity.The inhibitors of targeting 5-HTT / HDAC double target have both 5-HTT inhibitor effect and HDAC inhibitory effect, and are a kind of multi-target fluoxetine derivatives with 5-HTT and HDAC synergistically realizing antidepressant.The compound of the application is superior to fluoxetine compound in design strategy, introduces isoxazoles structure that can improve antidepressant activity, improves antidepressant activity, and has good improvement on the shortcomings of long treatment time and large side effects of currently used antidepressant compounds.

The present invention discloses a seco-C19 diterpenoid alkaloid compound, a preparation method thereof and an application thereof. The seco-C19 diterpenoid alkaloid compound provided by the present invention shows significant antidepressant activity in the mouse behavioral despair model experiment, which is significantly superior to the positive drug fluoxetine, and can be used for developing antidepressant drugs.

The application relates to the technical field of medicines, and discloses a diterpene alkaloid lappaconitine, a preparation method, a pharmaceutical composition and application. The diterpene alkaloid lappaconitine provided by the application shows significant antidepressant activity in a mouse behavioral despair model tail suspension test, is obviously superior to a positive drug fluoxetine, and can be used for developing antidepressant drugs.

The invention provides application of lactobacillus johnsonii YH1136 inactivated thalli in preparation of products for relieving depression, anxiety and sleep disorders, and relates to the technical field of microorganisms. The inactivated thallus is obtained by carrying out heat treatment on live thallus of lactobacillus johnsonii YH1136 with the preservation number of CCTCC NO: M 20221116 at 60 to 68 DEG C for 30 to 90 minutes. Animal experiments show that the inactivated thallus can significantly improve depression-like behaviors, anxiety-like behaviors and sleep disorders of CUMS model mice, and the effect of the inactivated thallus is equivalent to that of viable bacteria and positive drug fluoxetine, and is significantly superior to that of 100 DEG C traditional high-temperature inactivated thallus. The action mechanism is related to inhibition of HPA hyperfunction and up-regulation of hippocampal brain-derived neurotrophic factors and prefrontal cortex 5-hydroxytryptamine levels. The inactivated thallus provided by the invention is high in stability, good in safety and suitable for developing related drugs.

The application belongs to the technical field of plant polysaccharides, and specifically discloses a polygonatum sibiricum oligosaccharide, a preparation method thereof and application of the polygonatum sibiricum oligosaccharide in preparation of a medicine for treating depression. The polygonatum sibiricum oligosaccharide has a structure as shown in formula (I), is a novel structural acid-uniform oligosaccharide isolated from natural traditional Chinese medicinal materials polygonatum sibiricum for the first time, can effectively improve the depression-like behavior and sleep disorder of CUMS mice, and can reverse the depression-related biochemical index changes of the CUMS mice. The anti-depression effect of the polygonatum sibiricum oligosaccharide is equivalent to that of the existing classic medicine fluoxetine, but the side effect is obviously lower, and the polygonatum sibiricum oligosaccharide is expected to be developed into a new anti-depression drug.